Julie Kim | Takeda Pharmaceuticals
Julie Kim is president of the U.S. Business Unit, U.S. country head and member of Takeda’s Executive Team. The U.S. Business Unit portfolio encompasses gastroenterology, neuroscience, plasma-derived therapies and rare diseases.
She joined Takeda in 2019 through the acquisition of Shire, where she held several diverse roles with increasing responsibility. As part of Takeda, she became the president of the Plasma-Derived Therapies Business Unit, the position she occupied until April of 2022, when she became president of the U.S. Business Unit and U.S. country head.
Julie has 30 years of experience in health care, with leadership positions at global, regional, country and functional levels. In the biopharmaceutical industry, her experiences have spanned a variety of therapeutic areas, international market access, country and regional general management, marketing and emerging market development.
Julie is known for strong, collaborative and inclusive leadership that enables Takeda to meet the needs of the people the company serves while driving innovations that will improve patients’ lives. Her global outlook, a result of having worked in many countries in Europe, Asia and Latin America, as well as having lived in the U.K., Switzerland and the U.S., has helped her create teams that are diverse in multiple dimensions to enable inclusive decision-making that keeps the patient at the center.
She earned an MBA from the J. L. Kellogg Graduate School of Management at Northwestern University and a bachelor’s degree in economics from Dartmouth College. She resides with her family in the Boston area.